Global Drug Regulators And Manufacturers Grapple With How To Ensure Global Quality Standards (Part 1 Of 2)
This article was originally published in PharmAsia News
Executive Summary
KUALA LUMPUR, Malaysia - With global resources shrinking and the need for quality control in the drug supply chain greater than ever, regional solutions offer a look at how Asia fits into the regulatory scheme for assessing good manufacturing practices
You may also be interested in...
Voices From Emerging Markets Expected At Next ICH Steering Committee - APEC Harmonization Center Regulatory Conference
SEOUL - When ICH was created in 1990, Japan, U.S. and EU were the only participants, but more and more regulatory agencies are adopting variations of ICH guidelines for their own countries. In June, ICH's technical working groups will for the first time be expanded to include regional harmonization initiatives (RHIs), which regulators are calling a "dramatic change" towards global harmonization
Voices From Emerging Markets Expected At Next ICH Steering Committee - APEC Harmonization Center Regulatory Conference
SEOUL - When ICH was created in 1990, Japan, U.S. and EU were the only participants, but more and more regulatory agencies are adopting variations of ICH guidelines for their own countries. In June, ICH's technical working groups will for the first time be expanded to include regional harmonization initiatives (RHIs), which regulators are calling a "dramatic change" towards global harmonization
Japan’s PDMA Shifts Post-heparin Focus Of GMP Inspections Onto Asia
Japan's Pharmaceutical and Medical Device Agency will focus inspections for compliance with good manufacturing practices predominantly on Asian countries, the agency's inspection specialist, Ryoko Naruse, said during an Osaka seminar